After more than a decade and a half in development, the FDA’s Cardiovascular and Renal Drugs Advisory Committee today voted 8-3 against approval of Cytokinetics’ heart failure drug.
Adcomm members said the drug’s potential benefits did not seem to outweigh its risks, with panel members raising concerns about the drug’s...
